Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.80 |
| ▸ | GBA1 | P04062 | 4/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2268869 | 1.00 | FUCA1 (0.80) | FUCA1GBA1CYP2D6HRH4HRH3 | |
| SCHEMBL30287840 | 0.97 | FUCA1 (0.74) | FUCA1GBA1CYP2D6HRH4HRH3 | |
| SCHEMBL24008565 | 0.97 | FUCA1 (0.74) | FUCA1GBA1CYP2D6HRH4HRH3 | |
| SCHEMBL3262680 | 0.93 | FUCA1 (0.68) | FUCA1GBA1CYP2D6HRH4HRH3 | |
| SCHEMBL7637770 | 0.89 | FUCA1 (1.00) | FUCA1GBA1S1PR1S1PR5 | |
| SCHEMBL1860555 | 0.89 | FUCA1 (1.00) | FUCA1GBA1S1PR1S1PR5 | |
| SCHEMBL7637709 | 0.89 | FUCA1 (1.00) | FUCA1GBA1S1PR1S1PR5 | |
| SCHEMBL2713369 | 0.88 | GBA1 (0.83) | FUCA1GBA1CYP2D6 | |
| SCHEMBL5324079 | 0.88 | GBA1 (0.83) | FUCA1GBA1CYP2D6 | |
| SCHEMBL2713362 | 0.88 | GBA1 (0.83) | FUCA1GBA1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | SUMMIT CORPORATION PLC (GB) | 2011-09-29 | — | — | US | disclosed |
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | SUMMIT CORPORATION PLC (GB) | 2011-08-11 | — | — | US | disclosed |
| EP-2323651-A2 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | Summit Corporation Plc (GB) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010049678-A2 | TREATMENT OF ENERGY UTILIZATION DISEASES | SUMMIT CORPORATION PLC (GB) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010029313-A1 | ANTIINFECTIVE COMPOUNDS | SUMMIT CORPORATION PLC. (GB) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010015815-A2 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | SUMMIT CORPORATION PLC (GB) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | GAA, MAN2B1, GBA1 | FUCA1 17/4885GBA1 3/4885CYP2D6 1655/4885 |
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | GPI, GALE, HAVCR2 | FUCA1 83/4885GBA1 18/4885CYP2D6 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.